Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index; 198 of the 229 sources its claims cite were checked for support.

Evolution of multiple myeloma from a genomic perspective

Open access

Abstract

In this review, we explore the role of complex interactions between genomic evolution, environmental and genetic predispositions, and immune surveillance in disease progression from precursor conditions smoldering multiple myeloma and monoclonal gammopathy of undetermined significance to multiple myeloma (MM). MM has been described to be universally preceded by precursor states, often decades before it is even diagnosed. Genetic predisposition plays an important role in the initial transformation, and is driven by both germline variants and MM-specific loci influencing risk. The reported disparities in occurrence of precursor conditions and MM among racial groups highlights the role of predisposition and the need for broader cohort studies. Early genomic events, such as translocations and hyperdiploidy, are essential in precursor initiation. However, additional factors are usually needed to transform the precursor stages into symptomatic disease, such as positive selection of subclonal populations. This process is affected by aging and environmental factors, such as exposures to Agent Orange and agrochemicals. Therefore, integrating genomic and transcriptomic data with immune profiling or other clinical features is essential for identifying patients with high risk of progressing into MM. Here, we highlight the complexity of myelomagenesis, and underline the importance of state-of-the-art approaches for improved disease prediction.

Overview

CoChat Summary

TL;DR

This review integrates genomic, clinical, and temporal evidence to model how MGUS/SMM precursor conditions evolve into multiple myeloma through early initiating events, genetic predisposition, environmental exposures, and immune surveillance. It argues that many MM cases acquire their tumorigenic genomic profile early, with progression depending on subsequent clonal selection and immune escape.

Key findings

  • MM is universally preceded by precursor states MGUS/SMM, often decades before diagnosis; initiating events include IGH translocations and hyperdiploidy (HY). HY can start in the 2nd–3rd decade of life, with additional trisomies/aneuploidies acquired in subsequent decades; when HY and IGH co-occur (~10% of patients), HY always occurs after IGH. In >50% of patients, HY multi-gain events include non-odd chromosomes, most frequently 1q gain, and early 1q appears associated with more aggressive disease.
  • Progression is linked to RAS mutations, MYC translocations, APOBEC mutagenesis, and genomic complexity; these can already be observed in some MGUS and low-risk SMM years before progression. Molecular modeling estimates initiation of progressive SMM at approximately 30–40 years, while stable MGUS/SMM show a shorter lag of ~10–20 years; in IGH+HY cases, HY is acquired ~20 years before diagnosis.
  • The review proposes three MGUS/SMM groups: an immortalized but untransformed clone; a genomically transformed clone that remains stable under possible immune control (illustrated by the “MAFB paradox”); and a clone with both genomic transformation and immune escape, where progression is “merely a matter of time.”
  • Early intervention trials in high-risk SMM show progression-free survival benefit and one recent study demonstrated overall survival advantage, but the field lacks accurate prediction models; high-risk genomic features are underrepresented in SMM trials, and patients with mature MM genomic profiles typically fail to reach MRD negativity.

Methods

  • Narrative review integrating historical and recent studies to construct a model of myelomagenesis across temporal, clinical, and genomic dimensions.
  • Evidence base includes whole-genome sequencing, SNP arrays, FISH, mass spectrometry, single-cell RNA sequencing, immune profiling, molecular mathematical modeling, and interventional clinical trials; no new primary data are reported.
  • Main analysis is a synthesis of genomic evolution, genetic predisposition, environmental exposures, and immune surveillance from MGUS/SMM to MM.

Limitations

  • Stated: lack of large, racially heterogeneous cohorts from non-European ancestry limits genetic predisposition and racial disparity investigations; immune microenvironment studies have not defined how the microenvironment changes with external events; accurate prediction models for high-risk SMM are lacking; current MGUS/SMM definitions are clinically based and lack genomic features, immune status, or direct tumor-bulk assessment; early 1q findings need independent validation.
  • Evident: as a review, it reports no primary data; temporal models predict initiation timing only in the context of HY; spatial heterogeneity may not be captured by a single bone marrow investigation.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1182/blood.2024026313

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

70 Valid · 6 Not valid · 9 Not checked · 39 Own results and interpretations

94 more claims · 57 with their cited sources checked

Create a free account to see all 124 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 19
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Citations

Cites

Show all 113 references

Cited by

See all 8

Metadata

Authors
Maura, F., Samur, M., & Munshi, N.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Harvard University (US)
Corresponding author
Maura, Francesco
Venue
Blood
Published
2026-03-26
Volume
147
Issue
13
Pages
1423-1432
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W4417129847
Cited by
8
References
113
Citations by year
2026: 8
FWCI
1.35
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion)
Funders
National Cancer Institute (P30CA008748, P01CA155258, R37CA289752)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords
multiple myeloma, myelomagenesis, smoldering multiple myeloma, monoclonal gammopathy of undetermined significance, genetic susceptibility, germline mutations, hyperdiploidy, translocation, subclonal selection, immune surveillance, racial disparities, Agent Orange, agrochemical exposure, aging, disease progression, risk prediction
MeSH terms
Humans, Multiple Myeloma, Disease Progression, Evolution, Molecular, Genetic Predisposition to Disease, Genomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evolution of multiple myeloma from a genomic perspective. https://app.cochat.ai/papers/10.1182/blood.2024026313
The paper
Maura, F., Samur, M., & Munshi, N. (2026). Evolution of multiple myeloma from a genomic perspective. Blood. https://doi.org/10.1182/blood.2024026313

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.